23 February 2017
Here’s the introduction to their piece but we’d suggest you link through and read all the article.
We can safely say the that the pharmaceutical cannabis sector is approaching dealing with US Federal and state govt just like any other industry sector
British drug manufacturer GW Pharma and its American subsidiary, Greenwich BioSciences, have responded to Leafly’s report last week about the company’s attempts to move proprietary cannabidiol (CBD) bills through at least two state legislatures.
GW/Greenwich says it is not opposing medical marijuana or CBD access.
That report noted that the company’s lobbyists were moving in anticipation of the FDA’s expected approval of Epidiolex, a CBD-based drug that’s currently in Phase III trials. GW/Greenwich is pushing bills through legislatures in South Dakota and Nebraska, where all forms of cannabis medicine remain illegal. The bills would specifically make only FDA-approved forms of CBD legal under state law.
As Leafly reported, the effect of such a law would be to give GW/Greenwich a virtual monopoly on legal CBD sales—at least temporarily. The original story also noted that the company has recently hired local political lobbyists in at least nine states.
Read the full report at https://www.leafly.com/news/politics/gw-pharma-responds-not-creating-monopoly